Travere Therapeutics(DE:17R)
€33.000.00 (0.00%)
DE:17R
Travere Therapeutics ownership
€33.00
At close:0.00 (0.00%)
Travere Therapeutics (17R) Ownership - Who Owns Travere Therapeutics?
2 Followers
Travere Therapeutics (17R) Ownership Overview
- 1.47% Insiders
- 34.69% Mutual Funds
- 9.47% Other Institutional Investors
- 18.41% ETFs
- 35.96% Public Companies and Individual Investors
The ownership structure of Travere Therapeutics (DE:17R) stock is a mix of institutional, retail, and individual investors. Approximately 62.57% of the company’s stock is owned by Institutional Investors, 1.47% is owned by Insiders, and 35.96% is owned by Public Companies and Individual Investors.
The ownership structure of Travere Therapeutics (DE:17R) stock is a mix of institutional, retail, and individual investors. Approximately 62.57% of the company’s stock is owned by Institutional Investors, 1.47% is owned by Insiders, and 35.96% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Entrypoint Capital, Llc | €242,671 | |
| Dec 31, 2025 | Hussman Strategic Advisors Inc | €1,203,615 | |
| Dec 31, 2025 | Fisher Asset Management Llc | €1,298,987 | |
| Dec 31, 2025 | Woodline Partners Lp | €6,276,527 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Delaware Group Equity Funds V | 8,344,887 | Institution | 8.69% | 305,573,072 |
| BlackRock, Inc. | 8,020,663 | Institution | 8.36% | 293,700,638 |
| Vanguard | 6,704,484 | Institution | 6.98% | 245,504,795 |
| Ishares | 4,448,778 | Institution | 4.63% | 162,905,353 |
| Vanguard Index Funds | 4,014,262 | Institution | 4.18% | 146,994,246 |
| Joseph Edelman | 3,752,574 | Institution | 3.91% | 137,411,755 |
| Janus Investment Fund | 3,301,621 | Institution | 3.44% | 120,898,758 |
| Spdr | 2,629,156 | Institution | 2.74% | 96,274,434 |
| Fidelity Securities Fund | 2,386,891 | Institution | 2.49% | 87,403,175 |
| Steve Weber | 1,439,134 | Institution | 1.50% | 52,698,209 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Delaware Group Equity Funds V | 8,344,887 | Institution | 8.69% | 305,573,072 |
| Vanguard Index Funds | 4,014,262 | Institution | 4.18% | 146,994,246 |
| Janus Investment Fund | 3,301,621 | Institution | 3.44% | 120,898,758 |
| Fidelity Securities Fund | 2,386,891 | Institution | 2.49% | 87,403,175 |
| Vanguard Explorer Fund | 1,431,331 | Institution | 1.49% | 52,412,479 |
| Tiaa-cref Funds | 1,399,952 | Institution | 1.46% | 51,263,442 |
| Fidelity Concord Street Trust | 1,082,016 | Institution | 1.13% | 39,621,262 |
| Fidelity Salem Street Trust | 1,074,763 | Institution | 1.12% | 39,355,672 |
| Ivy Funds | 1,016,006 | Institution | 1.06% | 37,204,108 |
| Fidelity Select Portfolios | 798,843 | Institution | 0.83% | 29,252,033 |
FAQ
Who Owns Travere Therapeutics (DE:17R)?
According to the latest TipRanks data, approximately 62.57% of the company's stock is held by institutional investors, 1.47% is held by insiders, and 35.96% is held by public companies and individual investors.
What percentage of Travere Therapeutics (DE:17R) stock is held by institutional investors?
According to the latest TipRanks data, approximately 62.57% of Travere Therapeutics (DE:17R) stock is held by institutional investors: 34.69% by mutual funds, 18.41% by ETFs and 9.47% by other institutional investors.
What percentage of Travere Therapeutics (DE:17R) stock is held by retail investors?
According to the latest TipRanks data, approximately 35.96% of Travere Therapeutics (DE:17R) stock is held by public companies and individual investors.
Who owns the most shares of Travere Therapeutics (DE:17R)?
Delaware Group Equity Funds V owns the most shares of Travere Therapeutics (DE:17R).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
